Dermatol. praxi. 2020;14(3):142-146 | DOI: 10.36290/der.2020.026

Manifestations of psoriatic arthritis in patients with psoriasis

MUDr. Martina Skácelová, Ph.D., prof. MUDr. Pavel Horák, CSc.
III. interní klinika - nefrologická, revmatologická a endokrinologická, LF a UP Olomouc

Psoriatic arthritis is a severe chronic musculoskeletal disorder associated with psoriasis. In accordance to main clinical manifestations it can be divided into 5 subgroups (oligoarticular, polyarticular, DIP involvement, arthritis mutilans and axial form). Untreated or long term active disease can lead to severe destructive joint involvement, disability and progress of comorbidities. The CASPAR classification criteria are used in diagnosis, therapy is managed by the EULAR and GRAPPA recommendations. The approach to the patient is multidiciplinal, the first choice drug is methotrexate or other synthetic disease modifying drug, biologic treatment (TNF α, IL-12/23 or IL-17 inhibitors) is indicated in the case of inadequate therapeutic response, in the case of biologic treatment failure or contraindications inhibitors of PDE-4 are used.

Keywords: psoriasis, psoriatic arthritis, CASPAR criteria, methotrexate, biologic treatment.

Published: October 20, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Skácelová M, Horák P. Manifestations of psoriatic arthritis in patients with psoriasis. Dermatol. praxi. 2020;14(3):142-146. doi: 10.36290/der.2020.026.
Download citation

References

  1. Pavelka K, Vencovský J, Horák P, et al. Revmatologie, druhé aktualizované a rozšířené vydání. Maxdorf 2018; 394-422.
  2. Solmaz D, Eder L, Aydin SZ. Update on the epidemiology, risk factors, and disease outcomes of psoriatic arthritis. Best Pract Res Clin Rheumatol. 2018 Apr; 32(2): 295-311. doi: 10.1016/j.berh.2018. 09. 006. Epub 2018 Oct 5. Go to original source...
  3. Brockbank J, Gladman D. Diagnosis and management of psoriatic arthritis. Drugs 2002; 62: 2447. Go to original source... Go to PubMed...
  4. Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist‑diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013 Nov; 69(5): 729-735. doi: 10.1016/j.jaad.2013. 07. 023. Epub 2013 Aug 24. Go to original source...
  5. Spelman L, Su JC, Fernandez‑Peñas P, et al. Frequency of undiagnosed psoriatic arthritis among psoriasis patients in Australian dermatology practice. J Eur Acad Dermatol Venereol. 2015 Nov; 29(11): 2184-2191. doi: 10.1111/jdv.13210. Epub 2015 Sep 14. Go to original source... Go to PubMed...
  6. Villani AP, Rouzaud M, Sevrain M, et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta‑analysis. J Am Acad Dermatol. 2015 Aug; 73(2): 242-248. doi: 10.1016/j.jaad.2015. 05. 001. Epub 2015 Jun 6. Go to original source...
  7. Polachek A, Li S, Chandran V, Gladman D. Clinical enthesitis in a prospective longitudinal psoriatic arthritis cohort: Incidence, prevalence, characteristics and outcome. Arthritis Care Res (Hoboken) 2016. Go to original source...
  8. Haddad A, Chandran V. Arthritis mutilans. Curr Rheumatol Rep 2013; 15: 321. Go to original source... Go to PubMed...
  9. Gladman DD, Antoni C, Mease P, Clegg DO et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64 Suppl 2: ii14-17. Go to original source...
  10. Brockbank JE, Stein M, Schentag CT, Gladman DD. Dactylitis in psoriatic arthritis: a marker for disease severity? Ann Rheum Dis 2005; 64: 188. Go to original source...
  11. McGonagle D, Tan AL, Watad A. Pathophysiology, assessment and treatment of psoriatic dactylitis. Nat Rev Rheumatol. 2019 Feb; 15(2): 113-122. doi: 10.1038/s41584-018-0147-9. Go to original source... Go to PubMed...
  12. Sieper J, van der Heijde D, Landewé R. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum, DiS. 2009 Jun; 68(6): 784-788. doi: 10.1136/ard.2008.101501. Epub 2009 Jan 15. Go to original source... Go to PubMed...
  13. Pittam B, Gupta S, Harrison NL. Prevalence of extra‑articular manifestations in psoriatic arthritis: a systematic review and meta‑analysis. Rheumatology (Oxford). 2020 Mar 11. pii: keaa062. doi: 10.1093/rheumatology/keaa062. [Epub ahead of print] Go to original source... Go to PubMed...
  14. Abbouda A, Abicca I, Fabiani C, et al. Psoriasis and Psoriatic Arthritis‑Related Uveitis: Different Ophthalmological Manifestations and Ocular Inflammation Features. Semin Ophthalmol 2016; 1. Go to original source...
  15. Haroon M, Rafiq Chaudhry AB, Fitzgerald O. Higher Prevalence of Metabolic Syndrome in Patients with Psoriatic Arthritis: A Comparison with a Control Group of Noninflammatory Rheumatologic Conditions. J Rheumatol. 2016 Feb; 43(2): 463-464. doi: 10.3899/jrheum.150757 Go to original source... Go to PubMed...
  16. Eder L, Chandran V, Cook R, et al. The Risk of Developing Diabetes Mellitus in Patients with Psoriatic Arthritis: A Cohort Study. J Rheumatol. 2017 Mar; 44(3): 286-291. doi: 10.3899/jrheum.160861. Epub 2017 Feb 1. Go to original source... Go to PubMed...
  17. McDonough E, Ayearst R, Eder L, Chandran V, et al. Depression and anxiety in psoriatic disease: prevalence and associated factors. J Rheumatol. 2014 May; 41(5): 887-896. doi: 10.3899/jrheum.130797. Epub 2014 Apr 1. Go to original source... Go to PubMed...
  18. Jadon DR, Sengupta R, Nightingale A, et al. Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis. Ann Rheum, DiS. 2017 Apr; 76(4): 701-707. doi: 10.1136/annrheumdis-2016-209853. Epub 2016 Dec 2. Go to original source... Go to PubMed...
  19. Frediani B, Allegri A, Falsetti P, et al. Bone mineral density in patients with psoriatic arthritis. J Rheumatol. 2001 Jan; 28(1): 138-143. Go to PubMed...
  20. Taylor W, Gladman D, Helliwell P. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006 Aug; 54(8): 2665-2673. Go to original source...
  21. Schoels MM, Aletaha D, Alasti F, Smolen JS. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum, DiS. 2016 May; 75(5): 811-818. doi: 10.1136/annrheumdis-2015-207507. Epub 2015 Aug 12. Go to original source... Go to PubMed...
  22. Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum, DiS. 2016 Mar; 75(3): 499-510. doi: 10.1136/annrheumdis-2015-208337. Epub 2015 Dec 7. Go to original source... Go to PubMed...
  23. Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol. 2016 May; 68(5): 1060-1071. doi: 10.1002/art.39573. Epub 2016 Mar 23. Go to original source... Go to PubMed...
  24. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum, DiS. 2010 Jan; 69(1): 48-53. doi: 10.1136/ard.2008.102053. Go to original source... Go to PubMed...
  25. Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum, DiS. 2014 Jan; 73(1): 6-16. doi: 10.1136/annrheumdis-2013-203419. Epub 2013 Jun 8. Go to original source... Go to PubMed...
  26. Smolen JS, Schöls M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum, DiS. 2018 Jan; 77(1): 3-17. doi: 10.1136/annrheumdis-2017-211734. Epub 2017 Jul 6. Go to original source... Go to PubMed...
  27. Chandran V, Schentag CT, Gladman DD. Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. J Rheumatol. 2008 Mar; 35(3): 469-471. Epub 2007 Dec 15. Go to PubMed...
  28. Lie E, van der Heijde D, Uhlig T, et al. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate‑treated patients with rheumatoid arthritis. Ann Rheum, DiS. 2010 Apr; 69(4): 671-676. doi: 10.1136/ard.2009.113308. Epub 2009 Sep 9. Go to original source... Go to PubMed...
  29. Pincus T. Folic and folinic acid supplementation reduces methotrexate gastrointestinal side effects in rheumatoid arthritis. Clin Exp Rheumatol. 1998; 16(6): 667-668. Go to PubMed...
  30. Bello AE, Perkins EL, Jay R, Efthimiou P. Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis. Open Access Rheumatology : Research and Reviews. 2017; 9: 67-79. doi:10.2147/OARRR.S131668. Go to original source... Go to PubMed...
  31. Salliot C, van der Heijde D. Long‑term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum, DiS. 2009; 68(7): 1100-1104. Go to original source... Go to PubMed...
  32. Behrens F, Finkenwirth C, Pavelka K, et al. Leflunomide in psoriatic arthritis: results from a large European prospective observational study. Arthritis Care Res (Hoboken). 2013 Mar; 65(3): 464-470. doi: 10.1002/acr.21848. Go to original source... Go to PubMed...
  33. Asiri A, Thavaneswaran A, Kalman‑Lamb G, et al. The effectiveness of leflunomide in psoriatic arthritis. Clin Exp Rheumatol. 2014 Sep‑Oct; 32(5): 728-731. Epub 2014 Aug 4. Go to PubMed...
  34. Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996 Dec; 39(12): 2013-2020. Go to original source... Go to PubMed...
  35. Salvarani C, Macchioni P, Olivieri I, et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol. 2001 Oct; 28(10): 2274-2282.Další literatura u autorky a na www.dermatologiepropraxi.cz Go to PubMed...
  36. Fraser AD, van Kuijk AW, Westhovens R, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum, DiS. 2005 Jun; 64(6): 859-864. Epub 2004 Nov 4. Go to original source... Go to PubMed...
  37. Saougou I, Markatseli TE, Papagoras C, et al. Sustained clinical response in psoriatic arthritis patients treated with anti‑TNF agents: a 5-year open‑label observational cohort study. Semin Arthritis Rheum. 2011 Apr; 40(5): 398-406. doi: 10.1016/j.semarthrit.2010. 07. 004. Epub 2010 Sep 16. Go to original source...
  38. Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti‑IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non‑biological and biological anti‑tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double‑blind, placebo‑controlled, randomised PSUMMIT 2 trial. Ann Rheum, DiS. 2014 Jun; 73(6): 990-999. doi: 10.1136/annrheumdis-2013-204655. Epub 2014 Jan 30. Go to original source... Go to PubMed...
  39. Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab Inhibition of Interleukin-17 A in Patients with Psoriatic Arthritis. N Engl J Med. 2015 Oct; 373(14): 1329-1339. doi: 10.1056/NEJMoa1412679. Go to original source... Go to PubMed...
  40. Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double‑blind, placebo‑controlled period of the SPIRIT‑P2 phase 3 trial. Lancet. 2017 Jun 10; 389(10086): 2317-2327. doi: 10.1016/S0140-6736(17)31429-0. Epub 2017 May 24. Go to original source... Go to PubMed...
  41. Mease PJ, Gottlieb AB, van der Heijde D, et al. Efficacy and safety of abatacept, a T‑cell modulator, in a randomised, double‑blind, placebo‑controlled, phase III study in psoriatic arthritis. Ann Rheum, DiS. 2017 Sep; 76(9): 1550-1558. doi: 10.1136/annrheumdis-2016-210724. Epub 2017 May 4. Go to original source... Go to PubMed...
  42. Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med 2017; 377: 1525 Go to original source... Go to PubMed...
  43. Edwards CJ, Blanco FJ, Crowley J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis 2016; 75: 1065. Go to original source... Go to PubMed...
  44. Bond SJ, Farewell VT, Schentag CT, Gladman DD. Predictors for radiological damage in psoriatic arthritis: results from a single centre. Ann Rheum Dis 2007; 66: 370. Go to original source... Go to PubMed...
  45. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64 Suppl 2: ii14. Go to original source... Go to PubMed...
  46. Gladman DD, Hing EN, Schentag CT, Cook RJ. Remission in psoriatic arthritis. J Rheumatol 2001; 28: 1045. Go to PubMed...
  47. Gladman DD, Ang M, Su L, et al. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009; 68: 1131. Go to original source... Go to PubMed...




Dermatology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.